Particle.news
Economics ❯Healthcare Economics
Government Spending Prescription Drug Costs Medicare Savings Out-of-Pocket Expenses Taxpayer Impact Out-of-Pocket Costs Pharmaceutical Industry Medicaid Budget Public Spending Consumer Impact Staff Productivity Preventive Health Healthcare System Healthcare Funding Health Expenditure Obesity Treatment Consumer Spending Medicare Spending
The deal, which could reach $2 billion with milestones, positions GSK to target unmet needs in liver disease with a planned 2029 launch.
